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ABSTRACT It is now known that the ﬂexibility of the troponin T (TnT) tail determines thin ﬁlament conformation and hence cross-
bridge cycling properties, expanding the classic structural role of TnT to a dynamic role regulating sarcomere function. Here, using
transgenic mice bearing R-92W and R-92L missense mutations in cardiac TnT known to alter the ﬂexibility of the TnT tropomyosin-
binding domain, we found mutation-speciﬁc differences in the cost of contraction at the whole heart level. Compared to age- and
gender-matched sibling hearts, mutant hearts demonstrate greater ATP utilization measured using 31P NMR spectroscopy as
decreases in [ATP] and [PCr] and jDG;ATPj at all workloads and profound systolic and diastolic dysfunction at all energetic states.
R-92W hearts showed more severe energetic abnormalities and greater contractile dysfunction than R-92L hearts. The cost of
increasing contraction was abnormally high when [Ca21] was used to increase work in mutant hearts but was normalized with
supply of the b-adrenergic agonist dobutamine. These results show that R-92L and R-92W mutations in the TM-binding domain of
cardiac TnT alter thin ﬁlament structure and ﬂexibility sufﬁciently to cause severe defects in both whole heart energetics and
contractile performance, and that the magnitude of these changes is mutation speciﬁc.
INTRODUCTION
Muscle contraction occurs when the thick ﬁlament protein
myosin interacts with speciﬁc domains of the thin ﬁlament
protein actin, coupling the energy released from ATP hydro-
lysis (DG;ATP) by myosin to force generation. Availability
of these myosin-binding domains of actin for cross-bridge
formation depends on the interaction of the thin ﬁlament
regulatory proteins tropomyosin (TM) and the three troponin
(Tn) subunits, TnT, TnC, and TnI. Cross-bridge cycling
depends on both Ca21-dependent activation of TnC and
Ca21-independent conformational changes in TnT. The tail
portion of TnT binds to TM where the two TM polypeptide
chains overlap, changing the ﬂexibility of the thin ﬁlament
(1). This determines the afﬁnity of the TnT-TM complex for
actin, which in turn determines the availability of myosin-
binding domains on actin for cross-bridge formation. Experi-
ments using model systems have shown that changing the
TnT-TM interaction by deleting the TnT tail domain alters
actomyosin ATPase activity, in vitro motility of actin-TM
ﬁlaments on myosin heads, and cooperativity of myosin sub-
fragment-1 binding to thin ﬁlaments (2,3). Thus, in addition
to playing the classical structural role in the thin ﬁlament,
TnT also plays a crucial dynamic role in the regulation of the
contractile cycle and ATP utilization by the sarcomere.
Missense mutations in the tail portion of cardiac TnT
(cTnT) discovered by association with the cardiac disease
familial hypertrophic cardiomyopathy (FHC) have been shown
to lead to a cardiac phenotype characterized by contractile
dysfunction with modest or no left ventricular hypertrophy
and early sudden death (4). R-92 is a ‘‘hotspot’’, with many
FHC-associated missense mutations, each leading to a unique
progression of disease. R-92 is located in the elongated tail
domain of cTnT adjacent to the critical site of overlap of the
TM monomers. Our group has previously found that sub-
stituting glutamine (Q) for arginine (R) at residue 92 of cTnT
in transgenic mouse hearts increased the cost of contraction
assessed as decreased free energy available from ATP hydro-
lysis, jDG;ATPj, and abolished the ability of the heart to
increase contractile performance (5). This study showed that
changes in the structure of the TM-binding domain of cTnT
caused by the R-92Q missense mutation led to increased cost
of contraction at the whole heart level, but it has yet to be
tested whether this is unique to this mutation or whether all
FHC-associated mutations in this region of the thin ﬁlament
alter sarcomere dynamics and function leading to an increased
cost of contraction.
Recently, using molecular dynamics simulations, our group
found that substituting either tryptophan (W) or leucine (L)
for R at residue 92 of cTnT alters the ﬂexibility and dynamics
of the cTnT domain that binds to TM and that each mutation
yields a unique average conformation (6). Replacing 50%
of wildtype cTnT with cTnT bearing either the R-92W or
R-92L mutation in mice using genetic tools allowed us to
deﬁne the consequences of the changes in cTnT tail ﬂex-
ibility caused by these single amino acid replacements (6).
Both mutant hearts demonstrated ventricular and cellular
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remodeling and contractile dysfunction, but the changes for
R-92W hearts were more severe than for R-92L hearts. Thus,
each mutation led to unique peptide conformation and
dynamics and produced unique cardiac phenotypes in mice.
What is not known is whether the cost of contraction in-
creases in mouse hearts bearing either the R-92W or R-92L
mutation in cTnT, and, if so, whether the magnitude of the
change is mutation speciﬁc. Here, using these well-charac-
terized mice, we test the hypotheses that replacing R-92
in the TM-binding domain of cTnT with either R-92W or
R-92L leads to sufﬁciently large perturbations in thin ﬁlament
structure and sarcomere function to change sarcomere ener-
getics at the whole heart level and that the magnitude of the
changes is mutation speciﬁc. We deﬁned the energetic state
of the isolated perfused heart using the noninvasive tool of
31P NMR spectroscopy while simultaneously measuring con-
tractile performance.We found that hearts bearing R-92W and
R-92L mutations have distinct energetic phenotypes.
METHODS
Characteristics of R-92 mouse hearts
Twenty-three-week-old male mice bearing c-myc–tagged murine cTnT with
either the R-92L or R-92W cTnT mutation were generated as described (6);
sibling mice without mutation were used as nontransgenic (nTG) controls.
Each animal was genotyped by PCR-ampliﬁed tail DNA and restriction
enzyme digestion to conﬁrm the presence or absence of mutation codon. To
conﬁrm that the hearts studied here demonstrated the same gross morpho-
logic properties as hearts from R-92 mutant mice described by us previously,
body weight (BW), heart weight (HW), atrial mass, left ventricular (LV)
mass, the ratio of HW to BW, LV chamber volume, LV chamber radius and
wall thickness were determined (Table 1). BW was comparable among R-
92W, R-92L and nTG mice. HW, the ratio of HW to BW, LV mass and LV
wall thickness for R-92Lmice were larger than those in nTGmice, and much
larger than those for R-92W mice. HW, the ratio of HW to BW, LV mass
and LV chamber volume in R-92W mice were smaller than those for nTG
mice. Atrial mass for both R-92L and R-92W hearts were larger than that for
nTG hearts. Thus, in agreement with our previous report (6), transgenic hearts
used for this study bearing the R-92L mutation in cTnT were ;19% larger
than nTG hearts whereas hearts bearing the R-92W mutation were ;10%
smaller. Animals were maintained in accordance with National Institutes of
Health guidelines for the care and use of laboratory animals. The experi-
mental protocol was approved by the Standing Committee on Animals of
HarvardMedical Area and followed current National Institutes of Health and
American Physiologic Society guidelines.
Isolated perfused heart preparation
and measurement of isovolumic
contractile performance
Hearts were isolated and perfused in the Langendorff mode in a 10-mm glass
NMR tube as described (7). Brieﬂy, the chest was opened; the heart was
excised and arrested in ice-cold buffer, and connected via the aorta to the
perfusion cannula. Retrograde perfusion was carried out at a constant cor-
onary perfusion pressure of 75 mmHg at 37C with phosphate-free Krebs-
Henseleit (KH) buffer containing (in mM): NaCl, 118; KCl, 5.3; CaCl2, 2.5;
MgSO4, 1.2; EDTA, 0.5; NaHCO3, 25; and glucose, 10; equilibrated with
95% O2/5% CO2, yielding a pH of 7.4. Right ventricular drainage was ac-
complished by incision of the pulmonary artery. Efﬂuent from the Thebesian
veins was drained by a thin polyethylene tube (PE-10) pierced through the
apex of the left ventricle. A water-ﬁlled balloon custom-made of polyvinyl-
chloride ﬁlm connected to a pressure transducer (Statham P23Db, Gould
Statham, Medical Provision Department, Oxnard, CA) was used for con-
tinuous recording of left ventricular systolic pressure (LVSP) and heart rate
(HR) (7). The balloon matched the size of the ventricular cavity and was
inﬂated to set LV end diastolic pressure (EDP) to ;10 mmHg; the balloon
volume was then held constant. Isovolumic contractile performance data
were collected online at a sampling rate of 200 Hz using a commercially
available data acquisition system (MacLab; ADInstruments, Milford, MA).
LV developed pressure (DevP; the difference between LVSP and EDP), the
minimum and maximum values within a beat of the ﬁrst derivative of LV
pressure (1dP/dt and dP/dt), and rate-pressure product (RPP, i.e., product
of DevP and HR) were calculated ofﬂine. Coronary ﬂow rate was measured
by collecting coronary sinus efﬂuent through the suction tube (ml min1).
Experimental protocols
Three protocols were used. In the ﬁrst protocol, hearts (six each) from
R-92L, R-92W, and sibling nTG mice were perfused with KH buffer con-
taining 2 mM free Ca21 (total 2.5 mM); HR was not paced. After a 20-min
stabilization period, isovolumic contractile performance and 31P NMR spec-
troscopy were measured simultaneously for 24 min. Hearts were then per-
fused with KH buffer containing 3.5 mM free Ca21 (total 4.0 mM). After
steady state was reached (;4 min), cardiac function and 31P NMR spectros-
copy were measured simultaneously for another 24 min. In the second
protocol, HR was paced at 420 beats min1 (bpm) using monophasic square-
wave pulses delivered from a stimulator (model S88; Grass Instrument,
Quincy, MA) through salt-bridge pacing wires consisting of PE-90 tubing
ﬁlled with 4 M KCl in 2% agarose. Isovolumic contractile performance and
31P NMR spectroscopy were measured simultaneously when hearts were
perfused with KH buffer containing 2 and then 3.5 mM free Ca21, each for
24 min. In the third protocol, hearts from three R-92L, ﬁve R-92W, and six
nTG mice were perfused with KH buffer containing 2 mM free Ca21 and
paced at 420 bpm. After a 20-min stabilization period, isovolumic contrac-
tile performance and 31P NMR spectroscopy were measured simultaneously
for 24 min. Hearts were then studied unpaced at high workload achieved
by infusing dobutamine (ﬁnal concentration 300 nM) by a side-tube. After
steady state was reached, cardiac function and 31P NMR spectroscopy
were measured simultaneously for another 24 min. Based on preliminary
experiments, the doses of Ca21 and dobutamine used produced .90% of
the maximum contractile responses. At the end of each of these experiments,
hearts were removed from the perfusion apparatus, blotted, and weighed.
TABLE 1 Characteristics of nTG, R-92L, and R-92W mice
nTG R-92L R-92W
n 16 10 12
BW (g) 27.2 6 1.0 28.6 6 1.3 27.4 6 1.4
HW (mg) 115 6 4 137 6 4y 104 6 4*z
HW/BW (mg g1) 4.3 6 0.1 4.8 6 0.2* 3.8 6 0.1*z
Atrial mass (mg) 7.2 6 0.6 18.1 6 1.1y 15.9 6 1.5y
LV mass (mg) 86 6 2 99 6 2* 69 6 2yz
LV chamber volume (ml) 18 6 1 11 6 1y 11 6 1y
LV chamber radius (mm) 1.6 6 0.1 1.4 6 0.1y 1.4 6 0.1y
LV wall thickness (mm) 1.2 6 0.1 1.6 6 0.1y 1.2 6 0.1z
Protein (mg/mg wet
weight)
0.207 6 0.003 0.213 6 0.007 0.203 6 0.006
*p , 0.05.
yp , 0.01 vs. nTG.
zp , 0.05 vs. R ¼ 92L.
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The atria were removed, and the ventricles were rapidly frozen in liquid N2
and stored at 80C for subsequent biochemical assays.
31P NMR spectroscopy and calculation of
metabolite concentrations
Isolated perfused hearts were placed in a 10-mm glass NMR sample tube
and inserted into a custom-made 1H/31P double-tuned probe situated in an
89-mm bore 9.4-T superconducting magnet. To improve homogeneity of the
NMR-sensitive volume, the perfusate level was adjusted so that the heart
was submerged in buffer. 31P NMR spectra were obtained without proton
decoupling by using a 60 ﬂip angle, 15-ms pulse width, 2.4-s recycle time,
6,000-Hz sweep width and 2K data points at 161.94MHz on a GE-400 wide-
bore Omega spectrometer (General Electric, Fremont, CA). Single spectra were
collected during 12-min periods and consisted of data averaged from 312
free induction decays. Spectra were analyzed using 20-Hz exponential
multiplication and zero and ﬁrst-order phase corrections. The resonance areas
corresponding to ATP, phosphocreatine (PCr), and inorganic phosphate
(Pi) were quantiﬁed using Bayesian Analysis software (G.L. Bretthorst,
Washington University, St. Louis, MO). Bayesian Analysis software uses a
direct statistical analysis of the free induction decay amplitudes, which cor-
responds to the resonance areas (8). By comparing the amplitude under the
peaks from fully relaxed (recycle time 15 s) and those of partially saturated
(recycle time 2.4 s) spectra, the correction factors for saturation were cal-
culated for ATP (1.0), PCr (1.2), and Pi (1.15).
To determine the cytosolic concentration of ATP, the absolute resonance
amplitude corresponding to [g-P]ATP in the 31P NMR spectra during
baseline perfusion was normalized by heart weight. Since the Lowry protein
content (which minimizes detection of extracellular matrix protein and
thereby approximates myocyte protein) was indistinguishable among three
groups (Table 1), we make the assumption that the ratio of intracellular volume
to cardiac mass of 0.48 mL/mg wet weight was the same for all hearts (7). In
this case, amplitude units/g wet weight is directly proportional to the ab-
solute intracellular concentrations. The value of 10 mmol L1 for [ATP] for
nTG mouse myocardium (9) was used to calibrate the [g-P]ATP peak am-
plitude of the 31P NMR spectrum obtained during baseline perfusion period.
The mean of the amplitude of the [g-P]ATP resonances was used for this
calculation. Changes in ATP, PCr, and Pi concentrations during the proto-
cols were calculated by multiplying the ratio of their resonance peak am-
plitude to the mean amplitude of the [g-P]ATP peaks from the initial baseline
spectrum by 10 mmol L1. Intracellular pH was determined by comparing
the differences in the chemical shifts of Pi and PCr resonances in each
spectrum to values from a standard curve; the chemical shift of Pi but not
PCr varies with pH.
Cytosolic free [ADP] was calculated using the equilibrium expression for
the creatine kinase reaction and values for ATP, PCr, creatine (see below),
and H1 concentrations obtained by NMR spectroscopy and biochemical
assay: [ADP] ¼ ([ATP][ free creatine]) / ([PCr][H1]Keq), where Keq is 1.66 3
109 M1 for a [Mg21] of 1.0 mM. The free energy released by ATP hydro-
lysis (DG;ATP) drives the ATPase reactions in the cell. Although DG;ATP is a
negative value, the change in free energy state due to release of DG;ATP by
ATP hydrolysis is a positive value. Here we describe changes in DG;ATP
in absolute values, denoted as jDG;ATPj, and calculated as jDG;ATPj
(kJ/mol)¼ jDGo1 RT ln ([ADP][Pi] / [ATP])j, where DGo (–30.5 kJ/mol) is
the value of DG;ATP under standard conditions of molarity, temperature,
pH, and [Mg21], R is the gas constant (8.3 J/mol K), and T is the temperature
in degrees Kelvin.
Biochemical measurements
Five to ten mg of ventricular tissue was homogenized for 10 s at 4C in
potassium phosphate buffer containing 1 mmol L1 EDTA and 1 mmol L1
b-mercaptoethanol, pH 7.4 (ﬁnal concentration of 5 mg wet weight ml1).
Aliquots were removed for assay of protein (10) and total creatine (11)
contents.
Statistical analysis
All results are expressed as mean6 SE. Differences among the three groups
were compared by one-way factorial ANOVA followed by t-test, and changes
between baseline and high workload were compared by repeated-measure
ANOVA. Linear relationships were ﬁtted using least squares method.
All statistical analyses were performed with STATVIEW (Brain Power,
Calabasas, CA), and a value of p , 0.05 was considered signiﬁcant.
RESULTS
To determine whether alterations in thin ﬁlament structure
caused by substituting either L or W for R at position 92 of
cTnT are sufﬁcient to change whole heart energetics at
baseline and the cost of increasing contraction in a mutation-
speciﬁc manner, we used 31P NMR spectroscopy to simul-
taneously measure [ATP], [PCr], and [Pi] and indices of
systolic and diastolic performance in isolated hearts of age-
and sex-matched sibling R-92L, R-92W, and nTG mice. We
used three experimental protocols: 1), unpaced at baseline
conditions and during perfusion with high [Ca21] to increase
contractile performance; 2), paced both at baseline and
during perfusion with high [Ca21]; and 3), paced at baseline
and then unpaced during perfusion with dobutamine. Figs.
1 A and B shows representative 31P NMR spectra obtained
from nTG, R-92L and R-92W hearts acquired during base-
line perfusion and then at high workload in response to either
high [Ca21] or dobutamine. Mean values for [ATP], [PCr],
[Pi], and [ADP] are shown in Table 2. Fig. 2 A and B shows
corresponding representative tracings of isovolumic con-
tractile performance. Mean values for HR, DevP,1dP/dt and
dP/dt are shown graphically in Fig. 3; values for all indices
of systolic and diastolic function are given in Table 1 of the
Supplementary Materials.
R-92L and R-92W cTnT hearts have lower free
energy of ATP hydrolysis and lower contractile
performance at baseline
31P NMR spectra obtained from nTG hearts during baseline
perfusion showed typical high ratios of PCr to ATP (.1.8)
and PCr to Pi (.6). Compared to nTG hearts, R-92L hearts
had lower [ATP] (by ;16%) and [PCr] (by ;22%), and
higher [Pi] (;1.4-fold) and [ADP] (;1.3-fold). R-92W hearts
demonstrated even greater differences: [ATP] (;21%), [PCr]
(;29%), [Pi] (1.9-fold higher), and [ADP] (1.6-fold higher).
Intracellular pH was similar in all hearts and averaged 7.12.
The decreases in [PCr] in R-92L and R-92W hearts were not
due to decreases in total [creatine], which were not different
(27, 26, and 26mmol L1 for nTG, R-92L, and R-92W hearts,
respectively). Instead, the decrease in [PCr] is due to in-
creased ATP utilization.
Changes in [ATP], [ADP], and [Pi] can be expressed as a
single parameter, the free energy of ATP hydrolysis, DG;ATP.
This value represents the chemical driving force for the
ATPase reactions and describes the energy state of the cell.
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For well-oxygenated beating mammalian hearts, jDG;ATPj
is typically;60 kJ mol1 at low work states and;54–56 kJ
mol1 at high work states. As expected, jDG;ATPj for the
nTG hearts at low work states is;60 kJ mol1. Compared to
nTG hearts, jDG;ATPj is ;2.4 kJ mol1 lower for R-92L
hearts and even lower, by ;3.9 kJ mol1, for R-92W hearts
(Fig. 4).
During baseline perfusion of unpaced nTG hearts, LVSP
was;122 mmHg, the ratio of1dP/dt to –dP/dt was.1, and
RPP was ;40 3 103 mmHg min1, all values typical for
FIGURE 1 Representative 31P NMR
spectra from three to six 23-week-old
nTG (upper panels), R-92L (middle
panels) and R-92W (lower panels)
mutant hearts at baseline (left) and at
high workload (right) to 4 mM Ca21
(A) and in response to 300 nM dobuta-
mine (B). Resonance areas from left to
right correspond to Pi, PCr, and g, a,
and b-phosphates of ATP. At baseline,
R-92L hearts showed higher Pi reso-
nance area, but lower PCr and ATP
resonance areas than did nTG hearts,
R-92W hearts demonstrated even greater
differences compared with R-92L hearts.
nTG hearts exhibited an increase in Pi
resonance area, and decreases in PCr
resonance area, but similar ATP reso-
nance area at high workload in both A
and B compared with at baseline. R-92L
and R-92W hearts showed even greater
changes in Pi, PCr and ATP resonance
areas compared with at baseline as well
as nTG hearts at high workload. PPM,
parts per million.
TABLE 2 Energetics of hearts bearing cTnT mutations at baseline and at high workload in response to 4 mM Ca21 or 300 nM
dobutamine when not paced or paced at 420 bpm (n ¼ 3-6)
nTG R-92L R-92W
Unpaced Paced Dobutamine Unpaced Paced Dobutamine Unpaced Paced Dobutamine
Baseline
Pi (mM) 2.7 6 0.2 3.2 6 0.2 2.8 6 0.1 4.0 6 0.2y 4.5 6 0.2y 4.5 6 0.6y 5.1 6 0.3yz 6.0 6 0.2yz 6.8 6 0.3y{
PCr (mM) 18.2 6 0.3 18.2 6 0.4 19.5 6 0.1 14.1 6 0.3y 14.3 6 0.4y 15.4 6 0.7y 12.9 6 0.5yz 12.5 6 0.3yz 13.6 6 0.4yz
ATP (mM) 10.0 6 0.3 9.9 6 0.3 9.9 6 0.3 8.7 6 0.2y 8.1 6 0.2y 8.2 6 0.5y 7.9 6 0.2yz 7.5 6 0.3y 7.5 6 0.5y
ADP (mM) 35 6 2 35 6 3 35 6 1 55 6 2* 50 6 2* 44 6 3y 63 6 2y 62 6 2yz 55 6 4yz
High workload
Pi (mM) 6.0 6 0.2k 6.4 6 0.3k 8.4 6 0.4k 7.8 6 0.2yk 7.9 6 0.1yk 11.0 6 0.5yk 9.0 6 0.2yzk 9.0 6 0.2yzk 13.1 6 0.6yzk
PCr (mM) 13.5 6 0.2k 13.3 6 0.6k 13.8 6 0.1k 10.5 6 0.3yk 10.6 6 0.3yk 10.2 6 0.5yk 8.5 6 0.2yzk 8.6 6 0.3yzk 7.9 6 0.4yzk
ATP (mM) 9.8 6 0.3 9.6 6 0.4 9.6 6 0.5 7.7 6 0.1yk 7.6 6 0.3y 7.5 6 0.4y 6.9 6 0.2yz§ 6.6 6 0.3*z§ 6.4 6 0.2yz§
ADP (mM) 71 6 3k 73 6 3k 78 6 1k 89 6 6*k 83 6 7 *k 87 6 3*k 109 6 9*zk 100 6 6yzk 117 6 6yzk
Intracelluar pH in all hearts at baseline and high workload showed no differences, ranging from 7.08 to 7.13. DG;ATP is presented in Fig. 4. M, mol L
1.
*p , 0.05.
yp , 0.01 vs. nTG.
zp , 0.05.
{p , 0.01 vs. R-92L.
§p , 0.05.
kp , 0.01 vs. baseline.
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mouse hearts isolated and perfused in the Langendorff mode.
Increasing HR by ;18% by pacing at 420 bpm led to a
corresponding increase of ;15% in RPP with no change in
other indices of contractile performance. Whether R-92 mu-
tant mouse hearts were paced or unpaced, indices of both
systolic and diastolic contractile performance differed from
those for nTG hearts. Despite the larger size of the R-92L
hearts, all indices of systolic performance were lower for
R-92L hearts than for nTG hearts. Indices of systolic perfor-
mance for the smaller R-92W hearts were even lower. RPP,
the index of contractile performance that takes into account
changes in HR, LVSP, and EDP, was ;16% lower for
R-92L hearts and ;26% lower for R-92W hearts compared
to nTG hearts. The rate of relaxation was also lower for both
R-92L and R-92W hearts, with the slowest rate found for
R-92W hearts (22%).
Thus, for identical conditions of perfusate composition,
perfusion pressure, coronary ﬂow and temperature, and inde-
pendent of pacing status, hearts bearing R-92 cTnT missense
mutations have lower free energy of ATP hydrolysis, and the
driving force for ATPase reactions for R-92W hearts is even
lower than for R-92L hearts. Systolic performance and the
rate of relaxation were lower than for nTG hearts, with the
lowest values found for R-92W hearts.
R-92L and R-92W cTnT hearts demonstrate
decreased contractile reserve
We then compared the ability of the mutant hearts to abruptly
increase contractile performance, i.e., recruit their contractile
reserve, using two different agents that increase contractile
performance, high perfusate [Ca21] and dobutamine, an agent
that increases HR as well as force of contraction.
When perfusate [Ca21] was increased from 2.5 to 4 mM, all
hearts responded by increasing systolic and diastolic per-
formance. However, the mutation-speciﬁc differences in
contractile performance observed at baseline were not only
preserved, but the decreases in systolic and diastolic per-
formance observed for the R-92 mutant hearts became even
larger at high work states. Compared to nTG hearts, all in-
dices of systolic performance at high workloads for unpaced
hearts were ;25% lower for R-92L hearts and ;40% lower
FIGURE 2 Representative tracings
of isovolumic contractile performance
from three to six 23-week-old nTG (left
column), R-92L (middle column) and
R-92W (right column) mutant hearts at
baseline (left) and at high workload
(right) in response to 4 mM Ca21 (A)
and to 300 nM dobutamine (B). The
tracings from the top to the bottom
correspond to LVSP, HR, the mini-
mum and maximum values within a
beat of the ﬁrst derivative of LV
pressure (1dP/dt and dP/dt). R-92L
hearts showed the decreases in LVSP,
1dp/dt and dp/dt at baseline, and
decreased response to 4 mM Ca21 and
to 300 nM dobutamine compared with
nTG hearts. R-92W hearts demon-
strated even greater decrease in LVSP,
1dp/dt and dp/dt at baseline and
worse response to 4 mM Ca21 and to
300 nM dobutamine compared toR-92L
hearts. The heart was paced at 420 bpm
at baseline and at high workload in
response to 4 mM Ca21. The heart was
not paced when challenged with 300
nM dobutamine.
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for R-92W hearts. EDP did not increase for nTG hearts, but
increased by ;5 mmHg for both R-92L and R-92W hearts.
The rate of relaxation increased by ;2.0 for nTG, ;1.7 for
R-92L, and only ;1.3 times for R-92W hearts. A similar
pattern was observed for paced hearts. Thus, in response to
an abrupt increase in work caused by increasing external
[Ca21], paced and unpaced mutant hearts demonstrated both
systolic and diastolic dysfunction, and R-92W hearts ex-
hibited even greater systolic and diastolic dysfunction than
R-92L hearts.
The normal physiological response to supplying high
[Ca21] is to increase DevP without a change in HR whereas
in response to dobutamine both HR and DevP increase. How-
ever, since the increase in DevP with dobutamine is less than
with high [Ca21], RPP is only slightly higher with dobuta-
mine than in response to high [Ca21]. This response was
observed here for nTG hearts, but the mutant hearts dem-
onstrated greater sensitivity to dobutamine. Compared to nTG
hearts, mutant hearts had greater increases in HR, and al-
though DevP was always lower compared to nTG hearts,
RPP for mutant hearts increased more with dobutamine than
with high [Ca21]. The increases in RPP for the three chal-
lenges (high [Ca21] unpaced, high [Ca21] paced, and
dobutamine) were 28, 30, and 32 3 103 mmHg min1, re-
spectively for nTG hearts; 15, 17, and 293 103 mmHgmin1
for R-92L hearts; and 10, 10, and 243 103 mmHg min1 for
R-92W hearts. These results show that both mutant hearts
fail to recruit normal levels of contractile reserve in re-
sponse to high perfusate [Ca21] and that b-adrenergic stimu-
lation partially rescues their contractile reserve assessed as
the increase in RPP. The increase in EDP in mutant hearts was
also less with dobutamine; however, DevP and the rates of
tension development and relaxation were the same with
high [Ca21] and dobutamine. Importantly, the rescue with
dobutamine is more complete for R-92L hearts than for
R-92W hearts.
FIGURE 3 Contractile performance of hearts bearing
R-92 cTnT mutations under baseline perfusion conditions
(left columns) and at high workload (right columns) in
response to either 4 mM Ca21 when not paced or paced at
420 bpm or 300 nM Dobutamine. Data shown are mean6
SE, n ¼ 3–6. For the pairs from top to bottom: (A) heart
rate at baseline and (B) heart rate at high workload; (C)
developed pressure (difference between left ventricular
systolic pressure and end diastolic pressure) at baseline and
(D) developed pressure at high workload; (E) 1dp/dt at
baseline, and (F) 1dp/dt at high workload; (G) dp/dt at
baseline, and (H) dp/dt at high workload. *p, 0.05; yp,
0.01 vs nTG; zp , 0.05; kp , 0.01 vs. baseline.
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Mutation-speciﬁc differences in energetics
persist at high work states
As expected based on previous studies of mouse and other
rodent hearts comparing baseline and inotropic challenge
(12), increasing contractile performance led to a fall in [PCr]
and increases in [Pi] and [ADP] with either unchanged or only
slightly decreased [ATP] in all hearts. This pattern demon-
strates increased energy utilization due to increased work-
load at the whole heart level; i.e., the creatine kinase reaction
supplies sufﬁcient phosphoryl groups to closely match ATP
utilization at high workload by hydrolyzing PCr. Unlike the
mutation-speciﬁc differences in contractile performance found
in response to high [Ca21] and to dobutamine, changes in
values of [PCr], [Pi], and jDG;ATPj for the same physio-
logical challenge were similar for mutant and nTG hearts.
Consistent with greater energetic differences found for
R-92W hearts at baseline, only R-92W hearts demonstrated
a fall in [ATP] at all high work states. Thus the differences in
energetics observed at baseline among nTG and mutant hearts
persisted at high workload, but were not exacerbated at high
work states.
The cost of increasing contraction in response
to high [Ca21] and to dobutamine differed for
the mutant hearts but not for the nTG hearts
To assess the energetic cost of increasing isovolumic con-
tractile performance as opposed to deﬁning baseline ener-
getics, the relationships between RPP versus jDG;ATPj were
deﬁned for nTG, R-92L, and R-92W hearts for the three
protocols. The three upper panels in Fig. 4 allow compar-
isons among the three groups of hearts by experimental
protocol; the lower panels show the same results making
comparisons among the protocols for each type of heart.
Note that, in this representation, an increase in RPP results in
lower jDG;ATPj, i.e., the energy state of the heart becomes
FIGURE 4 Plots of the relationship between RPP and jDG;ATPj for nTG, R-92L and R-92W hearts under the three protocols: unpaced14 mMCa21, paced
14 mM Ca21 and paced1 300 nM dobutamine. RPP was from supplementary Table 1, jDG;ATPj was calculated from the data in Table 2. The equations, the
inverse of the slopes, the assessment of goodness for the linear ﬁts of data by group and by protocol are summarized in Table 3. (A) hearts from nTG (open
circles), R-92L (solid squares), and R-92W (solid triangles) were not paced both at baseline and high workload in response to 4 mM Ca21; (B) hearts from
nTG (open circles), R-92L (solid squares) and R-92W (solid triangles) were paced both at baseline and high workload in response to 4 mM Ca21; (C) hearts
from nTG (open circles), R-92L (solid squares), and R-92W (solid triangles) were paced at baseline but not paced at high workload in response to 300 nM
dobutamine; (D) nTG hearts were perfused by three protocols: unpaced-high calcium (open circles), paced-high calcium (solid squares) and dobutamine (solid
triangles); (E) R-92L hearts were perfused by three protocols: unpaced-high calcium (open circles), paced-high calcium (solid squares), and dobutamine (solid
triangles); (F) R-92W hearts were perfused by three protocols: unpaced-high calcium (open circles), paced-high calcium (solid squares), and dobutamine
(solid triangles). The number of trials is three to six.
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lower as a result of increasing work. Table 3 presents the
linear ﬁts of the data by group and protocol; the inverse of the
slope represents the energetic cost of increasing contraction
at the whole heart level.
For nTG hearts, the linear ﬁts for RPP versus jDG;ATPj
for the three protocols are indistinguishable, and the cost of
increasing contraction for each challenge is the same, ;0.15
kJ mol1/103 mmHg min1 (Fig. 4 D). The patterns for the
R-92L and R-92W hearts are strikingly different. Regardless
of the agent used to elicit an increase in contractile perfor-
mance, data for R-92W hearts fall to the left of data for
R-92L hearts, which in turn fall to the left of nTG hearts,
showing mutation-speciﬁc differences that are independent
of work state (Fig. 4, A– C). It can be seen that for any con-
stant RPP (see Fig. 4, A–C), values for jDG;ATPj for mutant
hearts are lower than for nTG hearts, demonstrating in-
creased cost of contraction that is mutation speciﬁc. For ex-
ample, for RPP of 40 3 103 mmHg min1, a typical baseline
value for nTG hearts, values for jDG;ATPj are 61, 57, and
55 kJ mol1 for nTG, R-92L, and R-92W paced hearts,
respectively (Fig. 4 B). Comparable differences are found at
all work states and for all protocols. Conversely, for the same
constant jDG;ATPj, mutant hearts have lower RPP, demon-
strating profound systolic dysfunction for the same energetic
state. For example, for jDG;ATPj of 56 kJ mol1 for paced
hearts challenged with high [Ca21] (Fig. 4 B), RPP generated
by R-92L hearts is ;61% of nTG RPP values, and R-92W
hearts generate only ;48% of nTG RPP values.
When high [Ca21] was used to increase contractile per-
formance for unpaced hearts, the cost of increasing contrac-
tion (inverse of the slopes of the linear ﬁts shown in Fig. 4
and given in Table 3) was nearly twice as high for R-92L as
for nTG hearts (0.28 vs. 0.15 kJ mol1/103 mmHg min1),
and the cost was even higher for R-92W hearts (0.38 kJ
mol1/103 mmHg min1). Pacing improved (i.e., lowered)
the cost of increasing RPP, especially for R-92L hearts, but
still remained high. When dobutamine was used as the chal-
lenge to increase contractile performance, a different pattern
was observed. Now, despite the persistent genotype-speciﬁc
leftward shifts for the relationships between RPP and jDG;ATPj,
the cost of increasing contraction was the same for all hearts
(0.16 kJ mol1/103 mmHg min1). These results suggest that
contractile reserve, but not the intrinsic energetic state, of myo-
cardium from R-92 cTnT mutant mice can be rescued, at least
in part, by b-adrenergic stimulation. These conclusions are the
same even if the cost of increasing contraction is adjusted for
the small differences in [ATP] observed for the three groups.
DISCUSSION
Changes in peptide dynamics due to R-92
missense mutations in cTnT lead to unique
cardiac phenotypes
Using molecular dynamic simulations to study the stability
and conformation of the cTnT peptide containing residues
70–170, our group previously reported that the presence of
either R-92L or R-92W mutation altered the ﬂexibility around
a hinge formed by residues 104–108, decreasing helical sta-
bility of the peptides. It was also found that the two muta-
tions differed in terms of motion quantiﬁed as the radius of
gyration, with little motion for the WT peptide and marked
oscillations for R-92L; motion for the R-92W peptide was
intermediate. Thus, each missense mutation at R-92 in cTnT
produced unique peptide dynamics. The consequences of
these changes in cTnT peptide dynamics for the functioning
of the intact sarcomere and for the whole heart cannot be
predicted. Here, using well characterized transgenic mouse
models, we report that replacing R-92 with either R-92L or
R-92W in cTnT produces unique energetic and contractile
phenotypes in intact beating hearts.
These observations that the cost of contraction and con-
tractile performance at all work states for R-92L and R-92W
cTnT hearts are severely impaired suggest that the structural
and dynamic changes in the thin ﬁlament caused by R-92
missense mutations in the TM-binding domain of TnT disrupt
the normal transmission of the Ca21-signaling cascade. This
could occur directly within the thin ﬁlament by disrupting
the transmission from the Ca21-sensor TnC to the TnT-TM
complex (13). It could also occur at the sarcomere level if the
entire sarcomere is structurally altered by the cTnT mutation
sufﬁciently to disrupt the titin-obscurin linkage between the
sarcomere and sarcoplasmic reticulum (14). Although the
details of how this occurs are not known, our study shows
that single amino acid replacements at R-92 in cTnT alter
peptide structure and dynamics in the thin ﬁlament in such a
way that contractile performance is impaired and cost of
contraction is increased at the whole heart level. Importantly,
this is the case independent of the presence or absence of
neurohumoral stimulation, changes in heart rate, and the
nature of the inotropic challenge, showing that contractile
dysfunction is due to the presence of the R-92 missense
mutations in cTnT (50% replacement). It is noteworthy that
mice bearing the FHC-associated missense mutation in the
TnT-binding site of TM at residue 180 (E-180G) also
demonstrate contractile dysfunction (15); the energetic state
TABLE 3 Linear regression parameters of RPP against
IDG~ATPI for nTG, R-92 mutant hearts for three protocols:
unpaced with high [Ca21], paced with high [Ca21], and
with dobutamine
Unpaced (r) 1/m Paced (r) 1/m Dobutamine (r) 1/m
nTG Y ¼ 6.5x 1 440 Y ¼ 6.8x 1 430 Y ¼ 6.3x 1 430
(0.90) 0.15 (0.92) 0.15 (0.99) 0.16
R-92L Y ¼ 3.6x 1 240 Y ¼ 4.9x 1 320 Y ¼ 6.4x 1 410
(0.85) 0.28 (0.94) 0.20 (0.96) 0.16
R-92W Y ¼ 2.8x 1 190 Y ¼ 3.2x 1 220 Y ¼ 5.9x 1 370
(0.80) 0.36 (0.66) 0.31 (0.97) 0.17
(r), assessment of goodness of ﬁt; 1/m, inverse of slope, kJ/103 mmHg
min1.
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was not deﬁned. Taken together, these results show that
altered peptide dynamics in this region of the thin ﬁlament
leads to contractile dysfunction at the whole heart level.
Results reported here show that substituting R at residue
92 in cTnT with either L or W also increase ATP utilization.
Whereas previous experiments using isolated skinned ﬁbers
from R-92L and R-92W cTnT hearts failed to show increased
tension cost (16,17), it is important to note that the original
R-92Q cTnT ﬁber studies did not show an effect on tension
cost until .90% mutant cTnT replacement was achieved. In
contrast, our earlier whole heart experiments using whole
hearts in which 50% R-92 was replaced with R-92Q clearly
showed increased tension cost (5). Thus, the threshold for
these two types of experiments differs (16,17). Our studies
were made using 23-week-old (adult) mice. During the life of
the animal it is reasonable to expect that altered sarcomere
structure and dynamics would lead to secondary molecular
alterations beyond the sarcomere. Important for our studies,
ATP supply pathways assessed as Vmax of key mitochondrial,
glycolytic, and phosphotransfer enzymes, are normal (not
shown), supporting our conclusion that the increased tension
cost is due primarily to ATP utilization.
R-92 cTnT mutations lead to increased cost of
contraction at all work loads
The conformational changes that occur in thick and thin
ﬁlament proteins during the contractile cycle are energeti-
cally unfavorable and must be coupled to the hydrolysis of
ATP to proceed. The chemical driving force for ATPase
reactions is quantitatively expressed as the free energy of
ATP hydrolysis, DG;ATP. Free energy available from ATP
hydrolysis is calculated as a constant value for ATP hydro-
lysis under standard conditions of temperature and molarity
corrected for actual concentrations of ATP and its products
of hydrolysis, ADP and Pi. Here we observe that hearts bear-
ing R-92W and R-92L missense mutations in cTnT have
lower [ATP] and [PCr], higher [ADP] and [Pi], and conse-
quently lower jDG;ATPj than age- and gender-matched nTG
sibling hearts. The changes are mutation speciﬁc, with R-92W
demonstrating greater differences than R-92L compared to
nTG hearts. This is the case for both baseline conditions and
high workloads, and is independent of the maneuver used to
increase work: pacing, high [Ca21] or dobutamine. These
changes in energy metabolites and in jDG;ATPj demonstrate
greater ATP utilization and show that altered sarcomere
dynamics and function caused by the missense mutations in
cTnT are sufﬁcient to increase ATP utilization determined at
the whole heart level. The observation that [ATP] as well as
[PCr] is lower than for normal heart shows that ATP uti-
lization exceeds the ability of the ATP-supply pathways to
maintain a constant [ATP]. Since work states achieved by
supplying dobutamine to the isolated heart mimic work states
typically observed in vivo, the mutant mice have a remark-
able ability to adapt to energy-poor conditions.
The differences in jDG;ATPj of 4–6 kJ mol1 observed
here for R-92L and R-92W cTnT hearts compared to nTG
hearts at both low and high work states, are unexpectedly
large. For comparison, the maximum fall in jDG;ATPj ob-
served for the normal intact heart during abrupt increases in
work is typically 6 kJ mol1. Replacing native aa- with bb-
myosin heavy chain in mouse hearts changed jDG;ATPj by
only 2–3 kJ mol1 (12), and, for all hearts studied here, the
further increase in RPP elicited by using dobutamine instead
of high [Ca21] led to a fall in jDG;ATPj of only;1 kJ mol1
change. One predicted consequence of such large deﬁcits in
jDG;ATPj for R-92 mutant sarcomeres would be to limit the
ability of the sarcomere to increase force development. Study-
ing intact hearts containing 50% mutant cTnT we observed
large deﬁcits in force development measured as DevP and in
the rates of tension development and relaxation, and reduced
ability to increase work upon acute challenge. ATPase reac-
tions can be controlled thermodynamically if the chemical
driving force for a particular reaction falls to its threshold.
Values of the free energy available from ATP hydrolysis
found here for the mutant hearts were close to the thermo-
dynamic limit for the sarcoplasmic reticular Ca21-ATPase
but not myosin ATPase (18).
High cytosolic concentrations of the end products of ATP
hydrolysis are sufﬁcient to alter cross-bridge cooperativity
and Ca21-sensitivity leading to reduced force development
and slower rates of relaxation. Recently Homsher et al. (19)
suggested that either slower ADP release or slower ATP
binding to myosin reduces shortening velocity. We suggest
that this could occur in hearts if [ADP] increased. For both
skeletal and cardiac muscle, when all other variables are con-
trolled, increases in [ADP] have also been shown to result in
greater diastolic dysfunction (20). The R-92 cTnT mutant
hearts studied here have lower [ATP] and higher [ADP] and
demonstrated decreased DevP and slower rates of tension
development and relaxation at all work states. Whereas local
regeneration of ATP in the sarcomere occurs by phospho-
transferase reactions associated with myoﬁbrillar proteins,
such as creatine kinase and adenylate kinase, it seems likely
that the cytosolic concentrations of ADP and ATP determined
here for the whole heart reﬂect changes in local concentra-
tions as well. It is noteworthy that R-92W cTnT hearts, with
more contractile dysfunction than R-92L cTnT hearts, had
lower [ATP] and higher [ADP], suffered loss of [ATP] at
high work states, and had lower jDG;ATPj than R-92L cTnT
hearts. These changes in [ATP] and [ADP] may contribute to
the contractile dysfunction observed in the mutant hearts.
b-Adrenergic stimulation normalizes the cost of
increasing contraction in R-92 cTnT mutant
hearts by increasing the rate of contraction,
not tension development
The large improvement in contractile reserve measured as
an increase in RPP and hence normalization in the cost of
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increasing contraction in response to dobutamine compared
to high [Ca21] was unexpected. This cannot be explained by
an improved energetic state because jDG;ATPj fell as RPP
increased with dobutamine supply, nor can it be explained by
changes in intracellular pH affecting sarcomere function, as
it was unchanged. Rather it is due to increased ATP turnover
in response to increased HR. RPP, an index of isovolumic
contractile performance, takes into account changes in rate of
contraction as well as tension development (DevP). The re-
lationship between RPP and jDG;ATPj show stepwise in-
creases in efﬁciency as HR increased by;70 bpm going from
unpaced to paced conditions and as HR increased another
70–80 bpm with dobutamine (Fig. 4, E and F). Importantly,
despite increases in HR, defects in DevP and rates of tension
development and relaxation persisted, consistent with im-
paired sarcomere function due to altered cTnT structure and
dynamics.
Increased cost of contraction is a common end
point of FHC-associated mutations of
sarcomeric proteins
Each FHC-associated missense mutation at R-92 in the
N-terminal tail domain of cTnT leads to a clinically distinct
cardiomyopathy. Our group has previously found that sub-
stituting glutamine (Q) for arginine (R) at residue 92 of cTnT
increased the cost of contraction at the whole heart level (5).
Increases in the cost of contraction have also been observed
in mouse hearts bearing the FHC-associated R-403Q muta-
tion in the actin-binding loop of myosin (21), and would
explain the observations that PCr to ATP ratio is lower in
hearts of patients with FHC due to mutations in many dif-
ferent sarcomere proteins (22). Taken together, these results
suggest the hypothesis that a common consequence of the
different FHC-associated mutations in sarcomeric proteins is
an increased cost of cardiac contraction. The results pre-
sented here using well characterized mice bearing mutations
R-92L and R-92W in cTnT provide a direct test of this
hypothesis. Our results show that substitution at R-92 in
the TM-binding domain of TnT with L (this study), W (this
study) or Q (5) increases the cost of contraction. Importantly,
they show that the increase in the cost of contraction is
mutation speciﬁc: the rank order for lower jDG;ATPj is L .
W . Q and directly corresponds to decreased contractile
performance (L.W. Q). These results provide a structural-
energetic basis for the unique cardiac phenotypes observed in
patients with contractile protein-associated FHC.
CONCLUSIONS
It is now known that the ﬂexibility of the TnT tail determines
thin ﬁlament conformation and hence cross-bridge cycling
properties, further expanding the classic structural role of TnT
to a dynamic role regulating sarcomere function (1,2). Changes
in cTnT ﬂexibility and dynamics have been found to differ
for each of three FHC-associated amino acid substitutions at
R-92 (6), suggesting a potential biophysical mechanism for
the mutation-speciﬁc phenotypes observed in patients with
cTnT-associated FHC. To directly model this system, we
used mouse hearts bearing different missense mutations at
R-92 of cTnT known to alter the ﬂexibility of the cTnT TM-
binding domain and found mutation-speciﬁc differences in
the cost of contraction at the whole heart level, profound
systolic and diastolic contractile dysfunction at all energetic
states, and impaired contractile reserve that was partially res-
cued by supplying the b-adrenoceptor-agonist dobutamine.
In all cases, R-92W cTnT hearts demonstrated greater
dysfunction than R-92L hearts. These ﬁndings suggest a
direct link between mutation-speciﬁc changes in the ﬂexi-
bility and dynamics of the cTnT N-terminal tail domain
caused by the R-92L and R-92W mutations and unique
cardiac clinical phenotypes that are characteristic of FHC.
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